• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 3:24:16 PM ET
    $PFNX
    Major Pharmaceuticals
    Health Care
    Get the next $PFNX alert in real time by email
    SC 13G/A 1 tm216208-3_sc13ga.htm SC 13G/A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. 2)*

     

     

    Pfenex Inc.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    717071104
    (CUSIP Number)
     
    12/31/2020
    (Date of Event Which Requires Filing of the Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     
     

     

    CUSIP: 717071104 Page 2

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    William Blair & Company, L.L.C.

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

     

    0

     

    6.

     

    SHARED VOTING POWER

     

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

     

    0

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    BD, IA

           

     

     
     
     

     

    CUSIP: 717071104 Page 3

     

     

    Item 1(a). Name of Issuer:
      Pfenex Inc.
    Item 1(b). Address of Issuer’s Principal Executive Offices:
      10790 Roselle Street, San Diego, CA 92121
       
    Item 2(a). Name of Person Filing:
      William Blair & Company, L.L.C.
    Item 2(b). Address of Principal Business Office or, if none, Residence:
      150 North Riverside Plaza, Chicago, IL 60606
    Item 2(c). Citizenship:
      Delaware
    Item 2(d). Title of Class of Securities:
      Common Stock
    Item 2(e). CUSIP Number:
      717071104
    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) x Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) o Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

     
     
     

     

    CUSIP: 717071104 Page 4

     

     

    Item 4. Ownership:
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 0
      (b) Percent of class: 0.00%
      (c) Number of shares as to which the person has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 0
    Item 5. Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. x
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      N/A
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
      N/A
    Item 8. Identification and Classification of Members of the Group:
      N/A
    Item 9. Notice of Dissolution of Group:
      N/A
    Item 10. Certifications:
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     
     
     

     

    CUSIP: 717071104 Page 5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

      Date:  2/11/2021
         
      By:  /s/ Ryan DeVore
         
      Name:  Ryan DeVore
         
      Title:  Partner, Head of Private Wealth Management
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, Provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

    (see 18 U.S.C. 1001).

     

     

     

    Get the next $PFNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PFNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PFNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - Pfenex Inc. (0001478121) (Subject)

      2/11/21 3:24:16 PM ET
      $PFNX
      Major Pharmaceuticals
      Health Care

    $PFNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors

      Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced the appointment of Evert (Eef) Schimmelpennink to its Board of Directors. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development, commercial growth, manufacturing, and business development. "I am pleased to welcome Eef Schimmelpennink to Pipeline's Board of Directors," said Carmine Stengone, President and Chief Executive Officer of Pipeline Therapeutics. "Eef is a renowned leader in the life-sciences industry whose cross-functional leade

      2/15/22 8:00:00 AM ET
      $IBIO
      $PFNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • TransCode Therapeutics Announces Key Appointments

      BOSTON--(BUSINESS WIRE)--TransCode Therapeutics today announced that it has recently elected a Chairman of its Board of Directors, appointed two new Independent Directors to the Board, and appointed a new member to its Advisory Board. Philippe Calais, Pharm D, Ph.D., President, Chief Executive Officer and a director of MatriSys Bioscience, Inc., has been elected Chairman of the Board of Directors of TransCode. Dr. Calais has served on TransCode’s Board of Directors since October 2018. With an extensive background in drug development, Dr. Calais’ experience has been instrumental in advancing TransCode’s lead therapeutic candidate, TTX-MC138, focused on treating metastatic cancer. T

      2/18/21 7:30:00 AM ET
      $ANAB
      $PFNX
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $PFNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors

      Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced the appointment of Evert (Eef) Schimmelpennink to its Board of Directors. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development, commercial growth, manufacturing, and business development. "I am pleased to welcome Eef Schimmelpennink to Pipeline's Board of Directors," said Carmine Stengone, President and Chief Executive Officer of Pipeline Therapeutics. "Eef is a renowned leader in the life-sciences industry whose cross-functional leade

      2/15/22 8:00:00 AM ET
      $IBIO
      $PFNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals